Abstracts tagged "Biomarkers"

Abstract Number: 0694 • ACR Convergence 2025
Treatment of Sjögren’s disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod
isabelle peene¹, Gwenny Verstappen², Joke Deprez³, Frans Kroese², Suzanne Arends², Andrew Kelly⁴, Lana Vandersarren⁵, Edward Bowen⁶, Julie Jacobs⁷, Paul Meyvisch⁸, Dirk Elewaut⁹ and Hendrika Bootsma¹⁰, ¹University Hospital Ghent, Ghent, Belgium, ²University Medical Center Groningen, Groningen, Netherlands, ³Ghent University, Ghent, Belgium, ⁴Argenx, Philadelphia, PA, ⁵Argenx, Boston, MA, ⁶IQVIA, Stevenage, United Kingdom, ⁷argenx, Ravels, Belgium, ⁸argenx, Ghent, Belgium, ⁹VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ¹⁰UMCG, Groningen, Netherlands
Background/Purpose: Background/Purpose Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration and progressive, immune-mediated dysfunction of the exocrine glands. Immunoglobulin (Ig)…
Abstract Number: 0873 • ACR Convergence 2025
Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis
Lihi Eder¹, Shangzhong Li², Philip J. Mease³, Christopher Ritchlin⁴, Walter P Maksymowych⁵, Hendrik Schulze-Koops⁶, Josef Smolen⁷, Oliver FitzGerald⁸, Vinod Chandran⁹, Chun Wu¹⁰ and Jinqi Liu², ¹University of Toronto, Toronto, ON, Canada, ²Bristol Myers Squibb, Princeton, NJ, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Rochester Medical Center, Canandaigua, NY, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, ⁷Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁸UCD, Dublin ⁶, Dublin, Ireland, ⁹Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, ¹⁰Bristol Myers Squibb, Princeton
Background/Purpose: PsA affects male and female patients equally; however, variations in manifestations and treatment response exist between sexes. Deucravacitinib is an oral, selective, allosteric tyrosine…
Abstract Number: 0758 • ACR Convergence 2025
Association Between Baseline IL-6 Levels and the Clinical Phenotype of Giant Cell Arteritis
Raquel Ugena-García¹, Clara Churtichaga Domenech², Judith Vidal-Ripoll², Francina salabert-Carreras², Cristina Calomarde-Gómez¹, Cristina Rocamora-Gisbert³, Irene Peralta-García⁴, Niccolo Viveros², Anne Riveros Frutos³, Ivette Casafont-Solé¹ and Judit Font-Urgelles¹, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, ³Hospital Germans Trias i Pujol, Barcelona, Spain, ⁴Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna. Karolinska University Hospital, Medical Unit of Gastroenterology, Dermatology, Rheumatology. Theme Inflammation and Ageing, Stockholm, Sweden
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in patients over the age of 50. Interleukin-6 (IL-6) has been shown to…
Abstract Number: 0406 • ACR Convergence 2025
Comparing biomarkers associated with uveitis in tear fluid and serum samples of children with Juvenile Idiopathic Arthritis
Ilaria Maccora¹, Mariia Pavlenko², Mekibib Altaye³, Hermine Brunner⁴, Margaret Chang⁵, Ashley Cooper⁶, Stefanie Davidson⁷, Alexandra Duell⁴, Bharti Gangwani⁵, Aimee Hersh⁸, Gary Holland⁹, Carl Langefeld¹⁰, Melissa Lerman¹¹, Mindy Lo⁵, Virginia Miraldi Utz⁴, Sampath Prahalad¹², Grant Schulert⁴, Megan Quinlan-Waters¹³, Erin Stahl⁶, Edmund Tsui⁹ and Sheila Angeles-Han¹⁴, ¹Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, ²Rheumatology Division, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, OH, ³Cincinnati Children's Hospital, Cincinnati, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Boston Children's Hospital, Boston, MA, ⁶Children's Mercy Kansas City, Kansas City, MO, ⁷Department of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, Philadelphia, PA, ⁸University of Utah, Salt Lake City, UT, ⁹UCLA Jules Stein Eye Institute and the Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, ¹⁰Wake Forest University School of Medicine, Winston Salem, NC, ¹¹Children's Hospital of Philadelphia, Philadelphia, PA, ¹²Emory + Children's Pediatric Institute, Atlanta, GA, ¹³Cincinnati Children's Hospital Medical Center, CCHMC, ¹⁴Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Chronic anterior uveitis (CAU) develops in 15-20% of juvenile idiopathic arthritis (JIA) cases. Early detection may prevent vision loss. However, known clinical risk factors…
Abstract Number: 0094 • ACR Convergence 2025
Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs
Sagrario Corrales¹, Laura muñoz-Barrera¹, Rafaela Ortega-Castro², Elena Moreno-Caño³, Jerusalén Calvo⁴, Concepción Aranda-Valera⁴, Lourdes Ladehesa⁵, Pilar Font⁶, Ismael Sanchez-Pareja¹, M Carmen Abalos-Aguilera⁷, Desiree Ruiz-Vilchez⁸, Christian Merlo⁹, MARIA ANGELES AGUIRRE ZAMORANO¹, Tomás Cerdó¹, Nuria Barbarroja¹⁰, Marta Alarcon-Riquelme¹¹, Alejandro Escudero Contreras⁴, Carlos Pérez Sánchez¹² and Chary López pedrera¹³, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁴IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁸Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, ⁹Rheumatology Service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/University of Cordoba/ Reina Sofia University Hospital, Córdoba, Spain, Cordoba, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, 20–40% of patients do not respond to biologic or targeted synthetic DMARDs (b/tsDMARDs). Understanding each drug’s molecular…
Abstract Number: 2584 • ACR Convergence 2025
Spatially Resolved Transcriptomics Reveal Macrophage Heterogeneity in Giant Cell Arteritis
Lea Dionet¹, Federica Pallotti², Margot Poux³, Quentin Delcros⁴, Nader Yatim⁵, Brian Soong⁶, Paul Breillat⁷, Kevin Chevalier⁸, claudie Cladière⁹, Patrick Bruneval¹⁰, Benoit Terris⁴, Alexis REGENT¹¹, Xavier Puéchal¹², Luc Mouthon¹³, Miriam Merad⁶, Olivia Lenoir¹⁴, Pierre-Louis Tharaux¹⁵, Maxime Samson¹⁶ and Benjamin Terrier¹⁷, ¹INSERM, Paris, France, ²Internal Medicine and Clinical Immunology, Rennes, France, ³Université de Paris, PARIS ⁰⁴EME, France, ⁴AP-HP, Paris, France, ⁵University of Paris-Cite, New York, NY, ⁶Mount Sinai School of Medicine, New York, ⁷INSERM, PARIS ¹⁷, Ile-de-France, France, ⁸Université Paris Cité, Montrouge, France, ⁹Marie et Louis Pasteur University, EFS, INSERM, UMR RIGHT, Besançon, France, Dijon, France, ¹⁰AP-HP, Paris, ¹¹Hopital Cochin, Paris, France, ¹²Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ¹³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ¹⁴Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, Ile-de-France, France, ¹⁵Paris Cardiovascular Research Center, Université Paris Cité, INSERM U⁹⁷⁰, Paris, France, PARIS, France, ¹⁶CHU Dijon Bourgogne, Dijon, France, ¹⁷Cochin Hospital, Paris, France
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis affecting individuals over 50 years of age. Current models implicate genetic susceptibility, immune senescence, activation of…
Abstract Number: 2325 • ACR Convergence 2025
Association of Galectin-3 and Myocardial Dysfunction in Patients with Psoriatic Arthritis
Natalia Guajardo-Jauregui¹, Iris J. Colunga-Pedraza², Dionicio A. Galarza-Delgado², Jose R Azpiri-Lopez³, Jesus Alberto Cardenas-de la Garza⁴, Diana E. Flores-Alvarado⁵ and Rosa Arvizu-Rivera⁶, ¹Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico
Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated condition associated with an increased risk of cardiovascular (CV) events due to disease-specific characteristics. Galectin-3 (Gal-3) is a…
Abstract Number: 2075 • ACR Convergence 2025
Ferritin trends differentiate anti-MDA5 Dermatomyositis from anti-Jo1 Antisynthetase Syndrome
Silvia Grazzini¹, Edoardo Conticini¹, Marco Fornaro², Chiara Rizzo³, Lidia La Barbera³, Maria Rosa Pellico⁴, Stefano Stano⁵, Florenzo Iannone⁶, Giuliana Guggino³, Nicoletta Del Papa⁴, Luca Cantarini⁷ and Bruno Frediani⁷, ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ²Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Italy., Bari, Italy, ³Rheumatology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo, Palermo, Italy, ⁴ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ⁵⁶. Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ⁶Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ⁷Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy
Background/Purpose: Serum ferritin (FERR) is a recognized marker of immune activation and a key laboratory feature of anti-MDA5 Dermatomyositis (DM). It has been increasingly studied…
Abstract Number: 1827 • ACR Convergence 2025
Transcriptomics and Machine Learning Unraveling the Molecular Drivers of PFAPA Flares
Sivia Lapidus¹, Tresa Ambooken², Ellen Hakim³, Tara Lozy⁴, Elahe Golalipour³, Sohail Adonimohammed⁵, Jennifer Weiss⁶, Suzanne Li⁶, Amanda Nowakowski⁷, Aryeh Lejtman⁸, Aaron Sebbag³, Ariel Aptekmann⁹ and Jigar Desai⁹, ¹Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Montclair, NJ, ²Food and Drug Administration, Floral Park, NY, ³Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, ⁴Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, ⁵Hackensack Meridian School of Medicine, Nutley, NJ, ⁶Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ, ⁷Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Hackensack, NJ, ⁸Joseph M. Sanzari Children's Hospital and Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, ⁹Center for Discovery and Innovation and Hackensack Meridian School of Medicine, Hackensack Meridian Health, Nutley, NJ
Background/Purpose: Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis (PFAPA) is the most common periodic fever presenting with frequent episodes of pain and impaired function. While…
Abstract Number: 1702 • ACR Convergence 2025
Powerful and Accurate Case-Control Analysis of Spatially Resolved Molecular Data in Autoimmune Disease
Yakir Reshef¹, Lakshay Sood¹, Michelle Curtis¹, Laurie Rumker², DANIEL STEIN³, Mukta Palshikar¹, Saba Nayar⁴, Andrew Filer⁵, Anna Helena Jonsson⁶, ilya Korsunsky⁷ and Soumya Raychaudhuri⁷, ¹Brigham and Women's Hospital, Boston, ²Broad Institute, Boston, ³Harvard University, Boston, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵The University of Birmingham, Birmingham, United Kingdom, ⁶University of Colorado School of Medicine, Aurora, CO, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) involve complex spatial organization of immune and stromal cells within inflamed tissues. As spatial molecular profiling methods…
Abstract Number: 1480 • ACR Convergence 2025
Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
CHEN-YU LEE¹, Rufei Lu², Carla Guthridge², Wade DeJager³, Jennifer Barnas⁴, Jennifer Anolik⁵, H Michael Belmont⁶, Judith James², Jill Buyon⁷, Brad Rovin⁸, Michelle Petri⁹, Joel Guthridge² and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴University of Rochester, Rochester, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶NYU School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸The Ohio State University, Columbus, OH, ⁹Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Early treatment is critical to prevent irreversible kidney damage in lupus nephritis (LN). Current guidelines recommend kidney biopsy when the urine protein-to-creatinine ratio (UPCR)…
Abstract Number: 1211 • ACR Convergence 2025
Plasma Levels of miR-133a-3p and miR-1-3p as Potential Biomarkers of Muscle Involvement and Initial Treatment Response in Myositis
Kristina Svobodová¹, Sabína Oreská¹, Lucia Vernerová², Dana Dlouhá³, Hana Wunsch², Karel Pavelka², Jiri Vencovsky⁴, Ladislav Šenolt⁵, Michal Vrablik⁶, Jaroslav Alois Hubáček³ and Michal Tomcik², ¹Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Experimental Medicine Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ⁴Institute of Rheumatology, Praha ⁸, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶³rd Department of Internal Medicine, General University Hospital and ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) involve muscle inflammation. MicroRNAs (miRNAs), such as miR-133a-3p and miR-1-3p, play a key role in gene regulation and muscle repair.…
Abstract Number: 0689 • ACR Convergence 2025
Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment
Blaz Burja¹, Paco Welsing², Alain Lescoat³, Andreas Eisenring⁴, Anna-Maria Hoffmann-Vold⁵, Claire Leroy David⁶, Dinesh Khanna⁷, Francesco Del Galdo⁸, Michele Iudici⁹, Janet Pope¹⁰, julia Spierings¹¹, Madelon Vonk¹², Marie-Elise Truchetet¹³, Martine Clergeau¹⁴, Michael Hughes¹⁵, Susan Murphy¹⁶, Tracy Frech¹⁷, Oliver Distler¹⁸ and Muriel Elhai¹⁹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, Utrecht, Netherlands, ³CHU Rennes - University Rennes, Rennes, France, ⁴Patient research partners, Zurich, Switzerland, ⁵Oslo University Hospital, Oslo, Norway, ⁶Patient research partners, Sos, France, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Leeds, Leeds, United Kingdom, ⁹Division of Rheumatology, Department of Medicine, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland, Geneva, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands, ¹²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹³Bordeaux University Hospital, Bordeaux, France, ¹⁴Patient research partners, Paris, France, ¹⁵Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ¹⁶Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Michigan, ¹⁷Vanderbilt University Medical Center, Nashville, TN, ¹⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹⁹Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland
Background/Purpose: Inflammatory joint and/or tendon involvement affects up to 30% of patients with systemic sclerosis (SSc), resulting in pain, reduced joint function, and impaired patients'…
Abstract Number: 0862 • ACR Convergence 2025
In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis
Margherita Giannini¹, Giulia Quiring², Mustapha Oulad-Abdelghani³, Béatrice Lannes¹, Yves Allenbach⁴, Olivier Benveniste⁵, Olivier Boyer⁶, Aleksandra Nadaj Pakleza¹, Bernard Geny⁷ and Alain Meyer⁸, ¹Strasbourg University Hospital, Strasbourg, France, ²University of Strasbourg, Strasbourg, France, ³IGBMC, Strasbourg, France, ⁴SORBONNE UNIVERSITE, Paris, France, ⁵Sorbonne Uniersite, Hopital de la Pitie-Salpetriere, Paris, France, ⁶University of Rouen, Rouen, France, ⁷UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; FranceExplorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg;, Strasbourg, Alsace, France, ⁸Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, Alsace, France
Background/Purpose: The aim of this study was to investigate whether in immune-mediated necrotising myopathy (IMNM), anti-HMGCR antibodies interfere with HMGCR activity and have a myopathic…
Abstract Number: 0752 • ACR Convergence 2025
Characterization of patients with polymyalgia rheumatica in the ARTESER giant cell arteritis cohort
Maite Silva-Diaz¹, Marta Domínguez-Álvaro², Rafael B. Melero-González³, Elisa Fernández-Fernández⁴, Jesús Alejandro Valero⁵, Ismael González⁶, Julio Sánchez Martín⁷, Javier Narváez⁸, Eva Galíndez Agirregoikoa⁹, Vicente Aldasoro Cáceres¹⁰, lydia Abasolo Alcazar¹¹, Javier Loricera¹², Noemí Garrido¹³, Santos Castañeda¹⁴, Carlota L Iñiguez¹⁵, Alicia Garcia¹⁶, Clara Molina Almela¹⁷, María Alcalde Villar¹⁸, Antonio Juan Mas¹⁹ and Ricardo Blanco²⁰, ¹Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Hospital Universitario Donosti, Donosti, Spain, ⁶Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ⁷Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁸Hospital Universitario de Bellvitge, Barcelona, Spain, ⁹BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁰Hospital Universitario de Navarra, Pamplona, Spain, ¹¹IdISSC. HCSC, Madrid, Madrid, Spain, ¹²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹³Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ¹⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁵Hospital del Bierzo, Ponferrada, Castilla y Leon, Spain, ¹⁶Rheumatologist, La Laguna, Spain, ¹⁷Consorci Hospital General Universitari de València, Valencia, Spain, ¹⁸Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, Madrid, Spain, ¹⁹Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain, ²⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Giant cell arteritis (GCA) is a chronic granulomatous vasculitis affecting medium- and large-sized arteries (1). The classic symptoms are cranial symptoms, including headache, jaw…

« Previous Page
1
…
6
7
8
9
10
…
109
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].